Bridging the gap: The future of biosimilars regulations

Anan S. Jarab Shrouq R Abu Heshmeh Ahmad Z. Al Meslamani a College of Pharmacy,Al Ain University,Abu Dhabi,UAEb AAU Health and Biomedical Research Center,Al Ain University,Abu Dhabi,UAEc Faculty of pharmacy,Department of clinical pharmacy,Jordan University of Science and Technology,Jordan
DOI: https://doi.org/10.1080/21645515.2024.2362450
2024-06-19
Human Vaccines & Immunotherapeutics
Abstract:Biosimilar vaccines and immunotherapeutic are innovative approaches in medical research. This commentary addresses the current disparities in regulations of biosimilar vaccines and immunotherapeutic products across different nations. It also navigates the benefits of global regulatory alignment and challenges that may be encountered. The current discrepancies in regulations across different countries, which pose significant challenges for the development and approval of biosimilar vaccines and immunotherapeutic products. These disparities often lead to delayed market access, increased development costs, and hindered innovation. The commentary stresses that such obstacles could be mitigated through harmonized regulations, resulting in faster approvals, reduced healthcare costs, and improved patient outcomes. Moreover, the commentary explores the specific complexities associated with biosimilar vaccines and immunotherapeutic, such as the intricate evaluation of biosimilarity due to their molecular composition and immunogenic properties. In conclusion, the editorial advocates for collaborative efforts to overcome the challenges in achieving global regulatory harmonization for biosimilars. This includes establishing uniform standards, fostering international cooperation among regulatory agencies, and promoting educational initiatives for healthcare providers and regulators. The ultimate goal is to ensure that patients worldwide have timely access to safe, effective, and affordable biosimilar treatments.
immunology,biotechnology & applied microbiology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is **the inconsistency of the global biosimilars regulatory framework**, and the challenges arising therefrom. Specifically, the paper explores the following key issues: 1. **Impact of current regulatory differences**: - There are significant differences in biosimilar regulatory standards among different countries and regions, which lead to market access delays, increased development costs, and hindered innovation. - For example, some countries require additional animal experiments or clinical trials, and these tests are considered unnecessary in many cases, wasting resources and prolonging the time to market. 2. **Necessity of global regulatory harmonization**: - Through harmonized regulations, the approval process of biosimilars can be accelerated, medical costs can be reduced, and patient prognosis can be improved. - The paper emphasizes the importance of international cooperation, including establishing consistent standards, promoting information sharing among regulatory agencies, and providing educational support for healthcare providers and regulators. 3. **Specific complexity and challenges**: - The molecular composition and immunogenicity characteristics of biosimilars make it complex to assess their similarity. - Different countries have different understandings of "interchangeability" and naming rules, further increasing the difficulty of harmonization. - Economic factors also affect the ability of countries to invest in and access biosimilars, especially in low - income countries. 4. **Legal and intellectual property issues**: - Legal issues such as patent protection may hinder the wide application of biosimilars, limiting their potential cost savings and accessibility improvements. ### Summary The core objective of the paper is to call for the harmonious unification of the global biosimilars regulatory framework through international cooperation and policy adjustment. This unification can not only accelerate drug development and approval speed, but also reduce medical expenses, enabling more patients to benefit from safe, effective and affordable treatment options.